Comparison
While FOXO4-DRI acts as a senolytic in preclinical models by promoting apoptosis of senescent cells, improving tissue function and healthspan measures in aged animals38, Retatrutide is an investigational agent that produces very large body-weight reductions in early trials by simultaneously engaging GLP-1R, GIPR, and GCGR to enhance satiety, energy expenditure, and glycemic control2575.
While FOXO4-DRI works as a D-retro-inverso peptide derived from a FOXO4 region that competes with endogenous FOXO4 for binding to p53, thereby releasing p53 to trigger apoptosis selectively in senescent cells38, Retatrutide is a triple incretin agonist peptide derived from a GIP backbone and engineered to activate GLP-1, GIP, and glucagon receptors, with non-natural residues and fatty-acid conjugation that confer long half-life and balanced multi-receptor signaling256575.
FOXO4-DRI is amino acids long, whereas Retatrutide is longer as it has a length of 39 amino acids. FOXO4-DRI is made up of a sequence of sequence data not available in the current dataset. Retatrutide is made up of a sequence of sequence data not available in the current dataset.
FOXO4-DRI
FOXO4
Retatrutide
Not assigned in the current dataset.